Biotechnology Market Research Reports
Biotechnology, one of molecular biology’s branches, monitored and intentional manipulation of biological organisms, processes or systems to effectively make or process drugs, or any other products and substances useful to enhancing people’s living quality. The earliest examples of humans applying their knowledge of biotechnology involved the efforts to enhance plants and animals’ species by cross-pollination (allogamy) or cross-breeding.
Biotechnology has recently turned to a more sophisticated business, considerably enlarged in scale and application range. Having goodly restored from the recession, the world Biotechnology Market is anticipated to be eventually estimated at far over EUR 245 billion by end-2015. However, with the numerous benefits this advanced technology comes laden with, there are worries about its potential misuse. Concerns over this issue has trailed into some attempting to facilitate the enforcement of specific laws constraining or even banning relevant programs and research (e.g. human cloning).
The research reports from this Catalogue offer a comprehensive outlook on the worldwide Biotechnology Market. The reports identify major market challenging forces and growth drivers, provide fresh statistics on the Biotechnology Industry, outline various trends and factors specifying the market’s direction, and more. Regional and country markets’ reviews are at hand in the reports too. Furthermore, companies with their innovations are discussed, and also short to long term forecasts are provided in the researches.
... of late stage failures of their drugs and to thereby curb R&D expenditure. Computational biology is also assisting in reducing the extensive use of humans in trials and ... the global market for computational biology by two main types of studies-cellular modeling and disease modeling. Each of these segments has ...May, 2013 112 pages
... further divided and analyzed by various product types offered by manufacturers. The market has also been segmented on the basis of end users into ... and others. The global cell culture market is segmented into the following categories: Cell Culture Consumables Market, by Products Media, by types Chemically ...May, 2013 126 pages
SUMMARY Provides comprehensive understanding and unprecedented access to discovery, preclinical and clinical stage partnering agreements entered into by the worlds leading ... and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where ...May, 2013 2360 pages
... , by Technology: Fermentation Tissue regeneration PCR technology Nanobiotechnology Chromatography DNA sequencing Cell based assay Others Biotechnology Market, by Application: Biopharmacy Bioservices Bioagriculture Bioindustrial The report provides a cross-sectional analysis of all the above ...Apr, 2013 115 pages
... legal literature. The report provides descriptive statistics of the 504 naked antibodies and their status during the study period of January 1, 2013 to ... the different in vitro and in antibody generation technologies. Attrition rate was defined as the percentage of failed antibodies of all active and inactive ...Mar, 2013 607 pages
China's demand for biotechnology products has grown at a fast pace in the past decade. In the next five years, both production and ... environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and ...Mar, 2013 349 pages
... data driven report contains over 30 links to online copies of actual preventative medicine deals and contract documents as submitted to the Securities Exchange ... easy access to each contract document on demand. Benefits Preventative Medicine Partnering 2007-2013 provides the reader with the following key ...Jan, 2013 100 pages
... deal. The initial chapters of this report provide an orientation of drug addiction partnering trends. Chapter 1 provides an introduction to the report, whilst chapter ... easy access to each contract document on demand. Benefits Drug Addiction Partnering 2007-2013 provides the reader with the following key ...Jan, 2013 100 pages
... recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during ... commodity volume is expected to be 12kg/a, sharing 10% of planned capacity. Global and China Monoclonal Antibody Industry Report, 2013 of ResearchInChina mainly involves the ...Jan, 2013 100 pages
India pharma rode on the wave of bunched up patent expiries in the US with many Para IV launches in 2012. In addition, it also benefited from the ... before 2016. Our growth outlook on Indian market continues to remain optimistic with 15-18% growth. This is based on the silent reforms in India that started ...Jan, 2013 50 pages
... closer – latest regulatory data update Which Mediterranean country might expect a generic sector average growth rate of 14.8% a year to 2016? The political, regulatory ... click on the title link below for more information. World Generic Markets A unique twice-monthly business publication which covers the ...Mar, 2012 552 pages
... dystrophy (DMD) and other antisense, RNAi drugs in the pipeline could see the final maturing of oligonucleotide based drug therapies. Global Biopharmaceutical Outlook 2013 of the Rising Stars sector released by MP Advisors provides an in depth analyses of biotech companies and their drug pipeline amidst ...Jan, 2013 109 pages
... and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term ... players continues to pour leaving room for surprises and volatility. Global Biopharmaceutical Outlook 2013 of the Mature Biotech sector released by MP Advisors provides ...Jan, 2013 110 pages
... some key therapy paradigms and may bring back innovation driven reputation of Japan Pharma. Edoxaban for Daiichi Sankyo, Canagliflozin for Mitsubishi Tanabe, and ... back into power replacing the short tenure of the Democratic Party of Japan (DPJ). LDP was the pioneer initiator of major healthcare reforms with ...Jan, 2013 146 pages
... (Value added innovation) versus regulatory pressures to contain costs. Global Biopharmaceutical Outlook 2013-Large Cap Pharma, released by MP Advisors provides analyses of ... Term 19. Sanofi: Solid Base Business, But Upside From Pipeline Will Take Longer To Come About 20. Global Pharma Sector Industry TablesJan, 2013 131 pages
... profiles of key players in the market, their business strategies and financial performance is also shared. The report provides a holistic assessment of the global bioinformatics market by segmenting it based on different parameters and analyzing winning strategies followed by stakeholders for every segment.Nov, 2012 127 pages
... past year. The report series allows you to view all the partnering and alliances deals announced worldwide. The initial chapters of this report ... assess suitability of your proposed deal terms for partner companies REPORT SCOPE Merger and Acquisition Yearbook 2013 series is intended to provide the reader ...Jan, 2013 200 pages
... leading healthcare companies during 2012 DESCRIPTION The Discovery Stage Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented ... , dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you ...Jan, 2013 200 pages
... access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2012 DESCRIPTION The Biotechnology Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the ...Jan, 2013 200 pages
... worlds leading healthcare companies during 2012 DESCRIPTION The Bigbiotech Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented ... 2012. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active bigpharma. Where the deal has an agreement ...Jan, 2013 200 pages